Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 positive
Therapy HX008 + Irinotecan
Indication/Tumor Type gastroesophageal junction adenocarcinoma
Response Type unknown


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive gastroesophageal junction adenocarcinoma unknown HX008 + Irinotecan Phase II Actionable In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). 33060149
PubMed Id Reference Title Details
(33060149) HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. Full reference...